Fiche centre
Universitaetsspital Basel
Basel — Switzerland
Essais liés5clinical trials
VilleBasellocalisation
PaysSwitzerlandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02051218
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Denosumab (reduced dosing) | Cancer | Phase 3 | NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | TERMINATED |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |